hotspot -WSS

hotspot

author：entertainment 2025-09-06 04:15:00 - browse：96

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Diverse clinical trials: Why aren’t we there yet?

WSS

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

PEPFAR is under serious threat — and so is global health

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Who are the detained American citizens released from prison in Iran?

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

The cancer drug shortage isn’t new — and neither are the solutions

Some of the ways extreme heat will change life as we know it

Affirmative action in medical school literally saved lives

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Medical leaders decry Supreme Court decision on affirmative action

Who are the detained American citizens released from prison in Iran?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals consider fixing cancer drug shortages on their own

New air purifier tech could be key to improving indoor air quality

Walmart eyes Medicare Advantage provider ChenMed

leisure time

New weight loss drugs vying to be the next Wegovy or Mounjaro

Target recalls 2.2 million additional candles due to laceration, burn hazards

Where are patients getting their prescriptions for GLP

Newly revealed memo details efforts to keep Trump in power following election loss

Target recalls 2.2 million additional candles due to laceration, burn hazards

FDA approves updated Covid vaccines

hotspot

focus

leisure time

entertainment